---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-035865"
form_type: "8-K"
ticker: "CTKB"
cik: "0001831915"
company_name: "Cytek Biosciences, Inc."
filed_at: "2023-02-13T23:59:59+00:00"
generated_at: "2026-06-19T16:40:04.197530+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cytek Biosciences to acquire flow cytometry & imaging assets from Luminex for $46.5M

## Summary
- Purchase price ~$46.5M cash; deal expected to close within 30 days; includes >7,000 installed instruments.
- Acquires Amnis imaging and Guava flow cytometers; >60% of FCI employees are commercial, boosting Cytek's sales and service.
- Acquisition aligns with DiaSorin's strategic priorities; Cytek expands global footprint and adds entry-level instrument options.
- Cytek to host investor conference call Feb 13 at 4:30 PM ET; details at investors.cytekbio.com.

## SEC filing metadata
- accession: 0001193125-23-035865
- form_type: 8-K
- ticker: CTKB
- cik: 0001831915
- company_name: Cytek Biosciences, Inc.
- filed_at: 2023-02-13T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/0001193125-23-035865-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/d446963d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-035865
- JSON: https://secwatch.observer/filing/0001193125-23-035865.json
- Plain text: https://secwatch.observer/filing/0001193125-23-035865.txt

## Key facts
- Material Agreements
  Cytek Biosciences, Inc. entered into Asset Purchase Agreement with Luminex Corporation valued at approximately $46.5 million in cash (effective 2023-02-13).
  - Action: entry
  - Agreement: asset purchase
  - Counterparty: Luminex Corporation
  - Value: approximately $46.5 million in cash
  - Effective: 2023-02-13
  source text: On February 13, 2023, Cytek Biosciences, Inc. (the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Luminex Corporation (“Luminex”), pursuant to which the Company agreed to acquire certain assets relating to the business of manufacturing, marketing, selling, servicing and maintaining Amnis-, CellStream-, Guava- and Muse-branded instruments, and flow cytometry reagent products and services of Luminex (the “Business”) for a purchase price of approximately $46.5 million in cash.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1831915/000119312523035865/0001193125-23-035865-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.